Recommendations of the fertility task force of the european society of gynecologic oncology about the conservative management of ovarian malignant tumors

International Journal of Gynecological Cancer

Volumn 21, Issue 5, 2011, Pages 951-963

  Morice, Philippe ^a,b   Denschlag, Dominik ^a   Rodolakis, Alex ^a   Reed, Nick ^a   Schneider, Achim ^a   Kesic, Vesna ^a   Colombo, Nicoletta ^a  

^a ESGO Task Force for Fertility Preservation in Gynecological Cancer   (Switzerland)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Borderline tumor; Conservative treatment; Epithelial tumor; Fertility; Nonepithelial tumor; Ovarian cancer; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ASCITES FLUID CYTOLOGY; BORDERLINE OVARIAN TUMOR; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHEMOSENSITIVITY; CONSERVATIVE TREATMENT; CYSTECTOMY; CYTOREDUCTIVE SURGERY; EPITHELIAL OVARIAN CANCER; FOLLOW UP; GERM CELL TUMOR; HUMAN; IMPLANT; MEDICAL SOCIETY; MUCINOUS BORDERLINE OVARIAN TUMOR; NONEPITHELIAL MALIGNANT OVARIAN TUMOR; OMENTECTOMY; OVARY CANCER; PERITONEAL BIOPSY; PRIORITY JOURNAL; REVIEW; SALPINGOOOPHORECTOMY; SEROUS BORDERLINE OVARIAN TUMOR; SEX CORD STROMAL TUMOR;

EID: 82955186363     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31821bec6b     Document Type: Review

References (91)

1. Denschlag D, Von Wolff M, Amant F, et al. Clinical recommendation on fertility preservation in borderline ovarian neoplasm: Ovarian stimulation and oocyte retrieval after conservative surgery. Gynecol Obstet Invest. 2010;70: 160-165.
2. Fauvet R, Poncelet C, Boccara J, et al. Fertility after conservative treatment for borderline ovarian tumors: A French multicenter study. Fertil Steril. 2005;83:284-290. (Pubitemid 40221778)
3. Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer. 1988;62:2212-2222. (Pubitemid 18261863)
4. Duvillard P. Tumeurs ovariennes á la limite de la malignité. Ann Pathol. 1996;16:396-405.
5. Gershenson D, Silva E, Levy L, et al. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer. 1998;82:1096-1103. (Pubitemid 28136523)
6. Gershenson D, Silva EL, Tortolero-Luna G, et al. Serous borderline tumors of the ovary with non invasive peritoneal implants. Cancer. 1998;83:2157-2163. (Pubitemid 28525397)
7. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol. 1996;20:1319-1330. (Pubitemid 26367203)
8. Kane A, Uzan C, Rey A, et al. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants. Oncologist. 2009;14:591-600.
9. Seidman JD, Kurman RJ. Treatment of micropapillary serous ovarian carcinoma (the aggressive variant of serous borderline tumors). Cancer. 2002;95:675-676. (Pubitemid 34839657)
10. Eichhorn JH, Bell DA, Young RH, et al. Ovarian serous borderline tumors with micropapillary and cribriform patterns: A study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol. 1999;23:397-409. (Pubitemid 29160000)
11. Tinelli R, Tinelli A, Tinelli FG, et al. Conservative surgery for borderline ovarian tumors: A review. Gynecol Oncol. 2006;100:185-191. (Pubitemid 41815071)
12. Morice P. Borderline tumours of the ovary and fertility. Eur J Cancer. 2006;42:149-158. (Pubitemid 43083483)
13. Swanton A, Bankhead CR, Kehoe S. Pregnancy rates after conservative treatment for borderline ovarian tumours: A systematic review. Eur J Obstet Gynecol Reprod Biol. 2007;135:3-7. (Pubitemid 350026161)
14. Yinon Y, Beiner ME, Gotlieb WH, et al. Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors. Fertil Steril. 2007;88:479-484. (Pubitemid 47212145)
15. Gotlieb W, Flikker S, Davidso B, et al. Borderline tumors of the ovary: Fertility treatment, conservative management, and pregnancy outcome. Cancer. 1998;82:141-146. (Pubitemid 28070490)
16. Camatte S, Rouzier R, Boccara-Dekeyser J, et al. Pronostic et fertilité aprés traitement conservateur d'une tumeur ovarienne á la limite de la malignité: Revue d'une série continue de 68 cas. Gynecol Obstet Fertil. 2002;30:583-591. (Pubitemid 34855539)
17. Lim-Tan S, Cajigas H, Scully R. Ovarian cystectomy for serous borderline. tumors: A follow-up study of 35 cases. Obstet Gynecol. 1988;72:775-780.
18. Papadimitriou DS, Martin-Hirsch P, Kitchener HC, et al. Recurrent borderline ovarian tumours after conservative management in women wishing to retain their fertility. Eur J Gynecol Oncol. 1999;20:94-97. (Pubitemid 29151446)
19. Zanetta G, Rota S, Chiari S, et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: A prospective study. J Clin Oncol. 2001;19:2656-2664.
20. Park JY, Kim DY, Kim JH, et al. Surgical management of borderline ovarian tumors: The role of fertility-sparing surgery. Gynecol Oncol. 2009;113:75-82.
21. Salomon LJ, Lhommé C, Pautier P, et al. Safety of simple cystectomy in patients with unilateral mucinous borderline tumors. Fertil Steril. 2006;85:1510.e1-1510.e4.
22. Morice P, Camatte S, El Hassan J, et al. Clinical outcomes and fertility results after conservative treatment for ovarian borderline tumor. Fertil Steril. 2001;75:92-96. (Pubitemid 32041230)
23. Ji H, Yliskoski M, Anttila M, et al. Management of stage-I borderline ovarian tumors. Int J Gynecol Obstet. 1996;54:37-44. (Pubitemid 26237909)
24. Romagnolo C, Gadducci A, Sartori E, et al. Management of borderline ovarian tumors: Results of an Italian multicenter study. Gynecol Oncol. 2006;101:255-260.
25. Donnez J, Munschke A, Berliere M, et al. Safety of conservative management and fertility outcome in women with borderline tumors of the ovary. Fertil Steril. 2003;79:1216-1221. (Pubitemid 36547864)
26. De Iaco P, Ferrero A, Rosati F, et al. Behaviour of ovarian tumors of low malignant potential treated with conservative surgery. Eur J Surg Oncol. 2009;35:643-648.
27. Palomba S, Zupi E, Russo T, et al. Comparison of two fertility-sparing approaches for bilateral borderline ovarian tumours: A randomized controlled study. Hum Reprod. 2007;22:578-585. (Pubitemid 46152583)
28. Gallot D, Pouly JL, Janny L, et al. Successful transfer of frozen-thawed embryos obtained immediately before radical surgery for a stage IIIA serous borderline ovarian tumor: Case report. Hum Reprod. 2000;15:2347-2350.
29. Lawal AH, Lynch CB. Borderline ovarian cancer, bilateral surgical castration, chemotherapy and a normal delivery after ovum donation and in vitro fertilizationYembryo transfer. BJOG. 1996;103:931-932. (Pubitemid 26297923)
30. Navot D, Fox JH, Williams M, et al. The concept of uterine preservation with ovarian malignancies. Obstet Gynecol. 1991;78:566-568.
31. Fain-Kahn V, Poirot C, Uzan C, et al. Feasibility of ovarian cryopreservation in borderline ovarian tumours. Hum Reprod. 2009;24:850-855.
32. Laurent I, Uzan C, Gouy S, et al. Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern. Ann Surg Oncol. 2008;15:3561-3566.
33. Laurent I, Uzan C, Gouy S, et al. Results after conservative treatment of serous borderline tumours of the ovary with stromal microinvasion but without micropapillary pattern. BJOG. 2009;116:860-862.
34. Winter WE III, Kucera PR, Rodgers W, et al. Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol. 2002;100:671-676. (Pubitemid 35300021)
35. Fauvet R, Boccara J, Dufournet C, et al. Restaging surgery for women with borderline ovarian tumors: Results of a French multicenter study. Cancer. 2004;100:1145-1151. (Pubitemid 38325941)
36. Camatte S, Morice P, Thoury A, et al. Impact of surgical staging in patients with macroscopic "stage I" ovarian borderline tumours: Analysis of a continuous series of 101 cases. Eur J Cancer. 2004;40:1842-1849. (Pubitemid 39036758)
37. Bostwick D, Tazelaar H, Ballon S, et al. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic Study of 109 cases. Cancer. 1986;58:2052-2065. (Pubitemid 16008783)
38. Tazelaar H, Bostwick D, Ballon S. Conservative treatment of borderline ovarian tumors. Obstet Gynecol. 1985;66:417-421.
39. Prat J, De Nictolis M. Serous borderline tumors of the ovary: A long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol. 2002;26:1111-1128. (Pubitemid 34969181)
40. Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors). Outcome-based study of 276 patients with long-term (95-year) follow up. Am J Surg Pathol. 2005;29:707-723. (Pubitemid 40734421)
41. Uzan C, Kane A, Rey A, et al. Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary. Ann Oncol. 2010;21:51-60.
42. Boran N, Cil AP, Tulunay G, et al. Fertility and recurrence results of consecutive surgery for borderline ovarian tumors. Gynecol Oncol. 2005;97:845-851. (Pubitemid 40824656)
43. Morris RT, Gershenson DM, Silvia EG, et al. Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol. 2000;95:541-547. (Pubitemid 30139573)
44. Zanetta G, Rota S, Lissoni A, et al. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynecol Oncol. 2001;81:63-66. (Pubitemid 32368079)
45. Uzan C, Kane A, Rey A, et al. How to follow up advanced-stage borderline tumours? Mode of diagnosis of recurrence in a large series stage IIYIII serous borderline tumours of the ovary. Ann Oncol. 2011;22:631-635.
46. Hart WR. Mucinous tumors of the ovary: A review. Int J Gynecol Pathol. 2005;24:4-25. (Pubitemid 40066450)
47. Ronnett BM, Kajdacsy-Balla A, Gilks CB, et al. Mucinous borderline ovarian tumors: Points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum Pathol. 2004;35:949-960. (Pubitemid 39037178)
48. Shappell HW, Riopel MA, Smith Sehdev AE, et al. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: Atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002;26:1529-1541. (Pubitemid 35387217)
49. Rodriguez IM, Irving JA, Prat J. Endocervical-like mucinous borderline tumors of the ovary: A clinicopathologic analysis of 31 cases. Am J Surg Pathol. 2004;28:1311-1318. (Pubitemid 39336369)
50. Rutgers JL, Scully RE. Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis. Cancer. 1988;61:340-348. (Pubitemid 18056494)
51. Bradley RF, Stewart JH 4th, Russell GB, et al. Pseudomyxoma peritonei of appendiceal origin: A clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006 May;30:551-559. (Pubitemid 44265007)
52. Ronnett BM, Shmookler BM, Sugarbaker PH, et al. Pseudomyxoma peritonei: New concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol. 1997;2:197-226.
53. Cho YH, Kim DY, Kim JH, et al. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors? Gynecol Oncol. 2006;103:878-882.
54. Koskas M, Uzan C, Gouy S, et al. Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). Ann Surg Oncol. 2011;18:40-48.
55. Zanetta G, Chiari S, Rota S, et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. BJOG. 1997;104:1030-1035. (Pubitemid 27400184)
56. Colombo N, Chiari S, Maggioni A, et al. Controversial issues in the management of early epithelial ovarian cancer: Conservative surgery and role of adjuvant therapy. Gynecol Oncol. 1994;55:S47-S51.
57. Schilder JM, Thompson AM, DePriest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002;87:1-7. (Pubitemid 36027095)
58. Morice P, Leblanc E, Rey A, et al. GCCLCC and SFOG. Conservative treatment in epithelial ovarian cancer: Results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Sociéte Francaise d'Oncologie Gynécologique). Hum Reprod. 2005;20:1379-1385. (Pubitemid 40790267)
59. Borgfeldt C, Iosif C, Måsbäck A. Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2007;134:110-114. (Pubitemid 47332804)
60. Park JY, Kim DY, Suh DS, et al. Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: Oncologic safety and reproductive outcomes. Gynecol Oncol. 2008;110:345-353.
61. Anchezar JP, Sardi J, Soderini A. Long-term follow-up results of fertility sparing surgery in patients with epithelial ovarian cancer. J Surg Oncol. 2009;100:55-58.
62. Satoh T, Hatae M, Watanabe Y, et al. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: A proposal for patient selection. J ClinOncol. 2010;28:1727-1732.
63. Schlaerth AC, Chi D, Poynor EA, et al. Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. Int J Gynecol Cancer. 2009;19:1199-1204.
64. Kajiyama H, Shibata K, Suzuki S, et al. Fertility-sparing surgery in young women with invasive epithelial ovarian cancer. Eur J Surg Oncol. 2010;36:404-408.
65. Kwon -S, Hahn HS, Kim TJ, et al. Fertility preservation in patients with early epithelial ovarian cancer. J Gynecol Oncol. 2009;20:44-47.
66. Morice P, Joulie F, Camatte S, et al. Lymph node involvement in epithelial ovarian cancer: Analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg. 2003;197:198-205. (Pubitemid 36927382)
67. Munnell EW. Is conservative therapy ever justified in stage I (IA) cancer of the ovary ? Am J Obstet Gynecol. 1969;103:641-650.
68. Benjamin I, Morgan MA, Rubin SC. Occult bilateral involvement in stage I epithelial ovarian cancer. Gynecol Oncol. 1999;72:288-291. (Pubitemid 29118183)
69. DiSaia PJ. Conservative management of the patient with early gynecologic cancer. CA Cancer J Clin. 1989;39: 135-154. (Pubitemid 19134210)
70. Kajiyama H, Shibata K, Suzuki S, et al. Is there any possibility of fertility-sparing surgery in patients with clear-cell carcinoma of the ovary? Gynecol Oncol. 2008;111:523-526.
71. Pautier P, Ribrag V, Duvillard P, et al. Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type. Ann Oncol. 2007;18:1985-1989. (Pubitemid 350286236)
72. Colombo N, Parma G, Lapresa MT, et al. Role of conservative surgery in ovarian cancer: The European experience. Int J Gynecol Cancer. 2005;15(suppl 3):206-211. (Pubitemid 43096583)
73. Wright JD, Shah M, Mathew L, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer. 2009;115:4119-4126.
74. Marpeau O, Schilder J, Zafrani Y, et al. Prognosis of patients who relapse after fertility-sparing surgery in epithelial ovarian cancer. Ann Surg Oncol. 2008;15:478-483.
75. Moore MM, Tewari K, Rose GS, et al. Long-term consequences following conservative management of epithelial ovarian cancer in an infertile patient. Gynecol Oncol. 1999;73:452.
76. Peccatori F, Bonazzi C, Chiari S, et al. Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients. Obstet Gynecol. 1995;86:367-372.
77. Mitchell PL, Al-Nasiri N, A'Hern R, et al. Treatment of nondysgerminomatous ovarian germ cell tumors: An analysis of 69 cases. Cancer. 1999;85:2232-2244. (Pubitemid 29215564)
78. Tewari K, Cappuccini F, Disaia PJ, et al. Malignant germ cell tumors of the ovary. Obstet Gynecol. 2000;95:128-133. (Pubitemid 30001642)
79. Low JJ, Perrin LC, Crandon AJ, et al. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer. 2000;89:391-398. (Pubitemid 30489889)
80. Zanetta G, Bonazzi C, Cantú M, et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol. 2001;19:1015-1020. (Pubitemid 32176276)
81. Tangir J, Zelterman D, Ma W, et al. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol. 2003;101: 251-257. (Pubitemid 36170125)
82. Zanagnolo V, Sartori E, Galleri G, et al. Clinical review of 55 cases of malignant ovarian germ cell tumors. Eur J Gynaecol Oncol. 2004;25:315-320. (Pubitemid 38585613)
83. Boran N, Tulunay G, Caliskan E, et al. Pregnancy outcomes and menstrual function after fertility sparing surgery for pure ovarian dysgerminomas. Arch Gynecol Obstet. 2005;271:104-108. (Pubitemid 40476238)
84. Ayhan A, Celik H, Taskiran C, et al. Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer. Eur J Gynaecol Oncol. 2003;24:223-232. (Pubitemid 36644604)
85. Brewer M, Gershenson DM, Herzog CE, et al. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol. 1999;17:2670-2675. (Pubitemid 29415222)
86. Gershenson DM, Miller AM, Champion VL, et al. Reproductive and sexual function after platinum based chemotherapy in long-term ovarian germ cell tumor survivors: A Gynecologic Oncology Group study. J Clin Oncol. 2007;19:2792-2797. (Pubitemid 47123188)
87. Kang H, Kim TJ, Kim WY, et al. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol. 2008;111:106-110.
88. de La Motte Rouge T, Pautier P, Duvillard P, et al. Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor. Ann Oncol. 2008;19:1435-1441.
89. Zhang M, Cheung MK, Shin JY, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary-an analysis of 376 women. Gynecol Oncol. 2007;104:396-400. (Pubitemid 46156957)
90. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003;21:1180-1189. (Pubitemid 46594151)
91. Reed N, Millan D, Verheijen R, et althe ESMO Guidelines Working Group. Non-epithelial Ovarian Cancer ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v31-v36.